JPMorgan raised the firm’s price target on Roche (RHHBY) to CHF 230 from CHF 220 and keeps an Underweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Recursion Pharmaceuticals’ (RXRX) Bold Acquisition Places it as an Industry Leader
- Jazz Pharmaceuticals (JAZZ) is Making Sweet Music with a Diverse Portfolio
- Arcus anti-TIGIT antibody differentiated from Roche’s, says Barclays
- Poseida Therapeutics (NASDAQ:PSTX) Stock Skyrockets on News of Roche Holdings Acquisition
- Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz
